Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential

Source Motley_fool

Explore the exciting world of Neurocrine Biosciences (NASDAQ: NBIX) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of Feb. 19, 2025. The video was published on March 26, 2025.

Should you invest $1,000 in Neurocrine Biosciences right now?

Before you buy stock in Neurocrine Biosciences, consider this:

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Neurocrine Biosciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $739,720!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of March 24, 2025

Karl Thiel has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Neurocrine Biosciences. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Why the S&P 500’s Path to 9,000 Runs Into Trouble in 2027The boldest S&P 500 forecast on Wall Street sees 9,000 by year-end, roughly 17% above where the index trades now. The fuel is the AI boom and a wall of idle cash.The warning is that the same AI trade
Author  Beincrypto
15 hours ago
The boldest S&P 500 forecast on Wall Street sees 9,000 by year-end, roughly 17% above where the index trades now. The fuel is the AI boom and a wall of idle cash.The warning is that the same AI trade
placeholder
Treasury Just Drew a Line in the Sand at 5.3%, and Bitcoin NoticedThe US Treasury said Wednesday it will at least double the size of its long-end debt buybacks. The 30-year yield reversed sharply from a 19-year high, and Bitcoin climbed past $65,000.The larger opera
Author  Beincrypto
15 hours ago
The US Treasury said Wednesday it will at least double the size of its long-end debt buybacks. The 30-year yield reversed sharply from a 19-year high, and Bitcoin climbed past $65,000.The larger opera
placeholder
Crypto Prices Explode With Surprise Rally: Is the Bull Market Back? Bitcoin (BTC) jumped 5.8% to levels above $69,500 on Wednesday, wiping out $1.23 billion in bets against it in one hour. Is the crypto bull market back?The rally ran market-wide, with Ethereum (ETH) u
Author  Beincrypto
15 hours ago
Bitcoin (BTC) jumped 5.8% to levels above $69,500 on Wednesday, wiping out $1.23 billion in bets against it in one hour. Is the crypto bull market back?The rally ran market-wide, with Ethereum (ETH) u
placeholder
Bitcoin is a “Cheat Code” to Retire Without Selling, Analyst Explains WhyBitcoin functions as a genuine cheat code for retiring without ever selling, according to analyst and entrepreneur Mark Moss, who laid out that thesis in a recent Coin Stories podcast interview.His ce
Author  Beincrypto
15 hours ago
Bitcoin functions as a genuine cheat code for retiring without ever selling, according to analyst and entrepreneur Mark Moss, who laid out that thesis in a recent Coin Stories podcast interview.His ce
placeholder
Eli Lilly Price Forecast: The Next Big Stock After Weight-Loss Drug Breakthrough?Eli Lilly is one of the most popular names today in America’s weight-loss and diabetes drug market. Its drugs delivered an average weight loss of 28.3% in a Phase 3 trial, approaching results historic
Author  Beincrypto
15 hours ago
Eli Lilly is one of the most popular names today in America’s weight-loss and diabetes drug market. Its drugs delivered an average weight loss of 28.3% in a Phase 3 trial, approaching results historic
goTop
quote